Revance Therapeutics, Inc. (RVNC)

3.6400 -0.1400 (-3.70%) At close: 04:00PM EDT

Revance Therapeutics, Inc.

1222 Demonbreun Street
Suite 2000
Nashville, TN 37203
United States
615 724 7755
https://www.revance.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 597

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Mark J. Foley	CEO & Director	1.26M	N/A	1965
Mr. Tobin C. Schilke	CFO & Principal Accounting Officer	731.58k	N/A	1975
Mr. Dwight O. Moxie	Chief Legal Officer & General Counsel	713.82k	N/A	1976
Jessica Serra	Head of Investor Relations & ESG	N/A	N/A	N/A
Ms. Jeanie D. Herbert	Senior Director of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Taryn Conway	Vice President of Marketing	N/A	N/A	N/A
Ms. Amie Krause	Chief People Officer	N/A	N/A	N/A
Dr. Conor Gallagher	Head of Medical Affairs & Aesthetics	N/A	N/A	N/A
Dr. David A. Hollander M.B.A., M.D.	Chief Medical Officer of Global Therapeutics Franchise Lead	N/A	N/A	1975
Ms. Erica Jordan	Chief Commercial Officer	N/A	N/A	1977

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Corporate Governance

Revance Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 7; Board: 6; Shareholder Rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.